ストックスクリーナーアプリを入手
10.04
1.86%
-0.19
アフターアワーズ：
10.03
-0.010
-0.10%
前日終値:
$10.23
開ける：
$10.35
24時間の取引高:
163.85K
Relative Volume:
0.63
時価総額：
$303.76M
収益：
$1.78M
当期純損益:
$-151.77M
株価収益率:
-1.7316
EPS:
-5.7981
ネットキャッシュフロー:
$-77.37M
1週間 パフォーマンス:
+13.57%
1か月 パフォーマンス:
+23.49%
6か月 パフォーマンス:
+44.88%
1年 パフォーマンス:
-8.39%
1日の値動き範囲:
$10.00
$10.69
1週間の範囲:
$8.745
$10.87
52週間の値動き範囲:
$5.60
$11.80
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
名前
Cartesian Therapeutics Inc
セクター
電話
301-348-8698
住所
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
10.04 | 309.51M | 1.78M | -151.77M | -77.37M | -5.7981 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | 開始されました | Wedbush | Outperform |
| 2024-12-19 | 開始されました | BTIG Research | Buy |
| 2024-08-06 | 開始されました | TD Cowen | Buy |
| 2024-07-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 開始されました | Oppenheimer | Outperform |
| 2024-05-24 | 開始されました | Mizuho | Buy |
| 2024-04-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-04-23 | 開始されました | Leerink Partners | Outperform |
| 2023-08-18 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 繰り返されました | Needham | Buy |
| 2022-06-06 | 開始されました | SVB Leerink | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-01-26 | アップグレード | Mizuho | Neutral → Buy |
| 2020-10-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-10-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | ダウングレード | Stifel | Buy → Hold |
| 2020-04-28 | 開始されました | H.C. Wainwright | Buy |
| 2020-01-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 開始されました | William Blair | Outperform |
| 2018-06-27 | 開始されました | Janney | Buy |
| 2017-03-30 | 繰り返されました | UBS | Buy |
すべてを表示
Cartesian Therapeutics Inc (RNAC) 最新ニュース
Cartesian (RNAC) Earnings Report: EPS Comes in Above Forecast in the Latest Reading; Market Reaction: The Stock Ends Up 14.02% in the Latest SessionEarnings Quality Score - vinanet.vn
Cartesian Therapeutics Inc. (NASDAQ: RNAC) Share Price, RNAC Stock News, RNAC Share Price & Updates - Kalkine
Cartesian (RNAC) Results at a Glance: EPS Prints Above Forecast in the Current Update; Latest Reaction: The Stock Gains 9.78% in the Latest ReadingCore Business Growth - vinanet.vn
Cartesian (RNAC) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison in the Latest Session; Closing Reaction: The Stock Gains 0.22% at the CloseMid-Term Outlook - vinanet.vn
RNAC Reiterated by Wedbush -- Rating Maintained at Outperform - GuruFocus
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | RNAC | US8162123025 - marketscreener.com
Barclays PLC (RNAC) discloses 1.76M-share, 5.99% holding in Cartesian Therapeutics - Stock Titan
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Lower Earnings Estimates for RNAC - MarketBeat
Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cartesian Therapeutics Advances RNA Cell Therapy Pipeline; Wedbush Sets $38 Price Target - RTTNews
RNAC Q2 2026 Earnings: Positive EPS Surprise Masks Pre-Revenue Biotech ChallengesMargin Improvement Report - vinanet.vn
Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
A Quick Look at Today's Ratings for Cartesian Therapeutics(RNAC.US), With a Forecast Between $25 to $44 - Moomoo
Cartesian Therapeutics Inc (RNAC) Stock News Today - TradingKey
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Four new employees get options for 115,250 Cartesian shares - Stock Titan
Cartesian Therapeutics earnings beat by $1.34, revenue fell short of estimates - Investing.com Canada
Cartesian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cartesian Therapeutics Q2 2026 earnings: R&D spending rises as Phase 3 advances - TradingKey
Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership - Quiver Quantitative
Cartesian Therapeutics reports Q2 2026: $149.3M cash; net income $15.8M; Phase 3 MG data expected 1Q27 - TradingView
Cartesian Therapeutics (Nasdaq: RNAC) Q2 earnings boosted by CVR revaluation - Stock Titan
Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC - Moomoo
RNAC Q2'26 Earnings: EPS estimate is (0.88) USD - TradingView
Cartesian Therapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
Price to sales forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cartesian Therapeutics (NASDAQ:RNAC) Raised to Hold at Zacks Research - MarketBeat
RNAC Q2'26 Earnings: revenue estimate is 179.67K USD - TradingView
Cartesian Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAC - TradingView
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 1.1%Here's What Happened - MarketBeat
Cartesian Therapeutics Inc (RNAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Cash Flow - TradingKey
Cartesian Therapeutics, Inc. Revenue Breakdown – FWB:1S70 - TradingView
Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cartesian Therapeutics Inc (RNAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RNAC|Cartesian Therapeutics Inc|Price:9.255|Chg%:+0.075 - TradingKey
Cartesian Therapeutics Inc (RNAC) Balance Sheet - TradingKey
Cartesian Therapeutics Inc (RNAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RNAC|Cartesian Therapeutics Inc|Price:7.780|Chg%:-0.100 - TradingKey
TradingKey - TradingKey
Cartesian Therapeutics, Inc. Revenue Breakdown – LS:A407YS - TradingView
ETFs Investing in Cartesian Therapeutics, Inc. Stocks - TradingView
JPMorgan Chase & Co. (RNAC) discloses 4.8% beneficial stake in Cartesian Therapeutics - Stock Titan
Cartesian Therapeutics Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid No RevenueTax Rate Impact - vinanet.vn
Enterprise value to EBITDA forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cartesian Therapeutics Inc (RNAC) - MSN
Cartesian Therapeutics Inc. : RNAC - 24/7 Wall St.
Cartesian Therapeutics Inc. (RNAC) Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue Pipeline ProgressTax Rate Impact - dars.gov.et
Cartesian Therapeutics Inc (RNAC) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):